Triple
T363289
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Genentech |
E7901
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object |
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
|
E46710
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a2e7e880008190a6ad7e06e5d03007 |
elicitation | completed |
| NER | batch_69a2ebd1016481909b8ba3b047a47145 |
ner | completed |
| NED1 | batch_69a3eca938988190b4490e086f25474e |
ned_source_triple | completed |
| NED2 | batch_69a3ee4e691481908f47635d5a7182c6 |
ned_description | completed |
| NEDg | batch_69a3ede6b21c8190bf5ca0347148c608 |
nedg | completed |
Created at: Feb. 28, 2026, 1:08 p.m.